In our study, Mykrobe predictor classified 3.5%/4.9% of our M. tuberculosis training/validation samples as having minor resistant populations, with median frequency of 6.8%/9.2%, respectively.
Exercise sessions occurred at a median frequency of three times per week, lasting a mean of 49 min (SD = 19) including warm-up and cooldown.
It is difficult to relate this to 1-year prevalence, although the latter must be higher, including people experiencing headache less than the median frequency of once a month.
This value approximately corresponds to the median frequency of occurrence of dij in Prdp.
The median frequency of HAdV detection was 30% of samples (range 2.0% to 64.7%).
The median frequency of ECFCs was 0.05/107 MNCs, with a range from 0 to 0.59/107 MNCs.
Median frequency of rosetting and platelet-mediated clumping was 3.0% (IQR [1.9 5.3]) and 7.2% (IQR [1.9 23.3]), respectively.
We found that the median frequency of surface Ig-positive subclones was nearly identical for CIB1+/+, CIB1+/−, and CIB1−/− cell lines, 4.5%, 3.9%, and 4.4%, respectively (Fig. 3D).
The HIV controllers also had a lower median frequency of Tregs than the ART-suppressed (3.9% vs. 5.0%, P = 0.008) and non-controllers (3.9% vs. 6.8%, P<0.001).
As compared to the CMV-seropositive, HIV-seronegative group, untreated participants with a recent HIV infection (n = 77) had a higher median frequency of pp65-specifc IFN-γ bright CD8+ T cells (0.31% vs. 0.67%, respectively, P = 0.02) and a similar median frequency of pp65-specifc IFN-γ bright CD4+ T cells (0.15% vs. 0.22%, P = 0.15; Figure 2).
Notably, the median frequency of the CCR7+ Treg subset was significantly higher in those that did not develop BOS than in those that did subsequently develop BOS (29.1% [14.3, 50.7] vs. 9.8% [7.8, 11.1] p = 0.04) (Figure 3).
